Hiroyuki Okuzawa, present COO and incoming CEO of Daiichi Sankyo, talks concerning the pharmaceutical firm’s product pipeline, together with its most cancers therapies, and its world partnerships with AstraZeneca and Merck.
Hiroyuki Okuzawa, present COO and incoming CEO of Daiichi Sankyo, talks concerning the pharmaceutical firm’s product pipeline, together with its most cancers therapies, and its world partnerships with AstraZeneca and Merck.